Close Menu

NEW YORK – Last Friday, BeiGene said that China's National Medical Products Administration approved its anti-PD-1 antibody tislelizumab for PD-L1 high expressing advanced or metastatic urothelial carcinoma patients who have progressed during or after platinum chemotherapy.

This marks the second approval in the country for tislelizumab after garnering approval last year for classical Hodgkin's lymphoma.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.